233 related articles for article (PubMed ID: 26351815)
1. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F; Diefenbach CS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
[TBL] [Abstract][Full Text] [Related]
2. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
4. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
[TBL] [Abstract][Full Text] [Related]
5. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Calabretta E; d'Amore F; Carlo-Stella C
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
Aldinucci D; Celegato M; Casagrande N
Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.
Casagrande N; Borghese C; Favero A; Vicenzetto C; Aldinucci D
Cancer Lett; 2021 Mar; 500():182-193. PubMed ID: 33326840
[TBL] [Abstract][Full Text] [Related]
8. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
9. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.
Aldinucci D; Gloghini A; Pinto A; De Filippi R; Carbone A
J Pathol; 2010 Jul; 221(3):248-63. PubMed ID: 20527019
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
Sánchez-Espiridión B; Martín-Moreno AM; Montalbán C; Figueroa V; Vega F; Younes A; Medeiros LJ; Alvés FJ; Canales M; Estévez M; Menarguez J; Sabín P; Ruiz-Marcellán MC; Lopez A; Sánchez-Godoy P; Burgos F; Santonja C; López JL; Piris MA; Garcia JF
Br J Haematol; 2013 Aug; 162(3):336-47. PubMed ID: 23725219
[TBL] [Abstract][Full Text] [Related]
11. Does rituximab have a place in treating classic hodgkin lymphoma?
Oki Y; Younes A
Curr Hematol Malig Rep; 2010 Jul; 5(3):135-9. PubMed ID: 20490723
[TBL] [Abstract][Full Text] [Related]
12. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
[TBL] [Abstract][Full Text] [Related]
13. Targetable molecular pathways in classical Hodgkin's lymphoma.
Adams H; Obermann EC; Dirnhofer S; Tzankov A
Expert Opin Investig Drugs; 2011 Feb; 20(2):141-51. PubMed ID: 21204722
[TBL] [Abstract][Full Text] [Related]
14. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
Aldinucci D; Borghese C; Casagrande N
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096713
[TBL] [Abstract][Full Text] [Related]
15. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases.
Loo EY; Medeiros LJ; Aladily TN; Hoehn D; Kanagal-Shamanna R; Young KH; Lin P; Bueso-Ramos CE; Manning JT; Patel K; Thomazy V; Brynes RK; Goswami M; Fayad LE; Miranda RN
Am J Surg Pathol; 2013 Aug; 37(8):1290-7. PubMed ID: 23774171
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
17. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Liu WR; Shipp MA
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
[TBL] [Abstract][Full Text] [Related]
19. [The molecular pathology of classical Hodgkin lymphoma].
Asano N
Rinsho Ketsueki; 2015 Oct; 56(10):2024-31. PubMed ID: 26458441
[TBL] [Abstract][Full Text] [Related]
20. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
